Please login to the form below

Not currently logged in
Email:
Password:

Novartis face $590m impairment charges

Novartis will face impairment charges of $590m following the discontinued development of two investigational compounds

Novartis will face total impairment charges of $590m following the discontinued development of the investigational compounds Mycograb (efungumab), an antifungal treatment for invasive candidiasis in adults, and albinterferon alfa-2b, being assessed as a therapy for chronic hepatitis C.

According to the company, the decision to halt the development of the compounds reflected an "enhanced focus on differentiated medicines most likely to address unmet medical needs."

Feedback from regulatory authorities in the EU and US, as well as data from a recent phase II study involving albinterferon alfa-2b, were also said to have contributed towards the choice.

Impairment and related charges for the Swiss company concerning the discontinuation of albinterferon alfa-2b come to $230m, with a further $390m in charges over the decision to halt Mycograb development.

Impairment charges are a reduction in the value of a company based on poor estimates regarding a company's intangible assets.

These charges will be reflected in Novartis' third quarter results.

The company said the charges will be partially offset through the sale of US rights for overactive bladder treatment Enablex (darifenacin) to Warner Chilcott for $400m.

A statement from Novartis said it expects a gain of around $390m to be recorded in the fourth quarter of 2010.

5th October 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Empowering Strategic Performance Ltd

OUR GOAL: To help clients Metamorph™ Science into Action that changes healthcare to improve the lives of patients. Empowering Strategic...

Latest intelligence

Planning your clinical trial? Why you need to engage patients sooner
It’s highly likely that clinical studies are deterring patients based on decisions made in the early stages, such as during planning and design....
Patient-centricity in improving patient recruitment advertising
This blog looks into the importance of concepts and patient centricity in patient recruitment....
AI and life sciences
AI: the smart money is on the smart thinking
Looking at the three key areas where AI is being applied: drug discovery, clinical decision-making and clinical trials...

Infographics